17/05/2026
Chronic kidney disease almost always ends in dialysis. A new injection may prevent that.
The FDA has officially approved Voyxact (sibeprenlimab-szsi), a first-of-its-kind at-home treatment for adults battling primary immunoglobulin A nephropathy (IgAN).
This rare but serious condition causes the immune system to attack the kidneys, leading to chronic inflammation and potential organ failure. Voyxact works by targeting a specific protein called APRIL, effectively blocking the production of the abnormal antibodies that cause kidney damage. For patients who have struggled to control the disease with standard therapies, this monthly self-injection offers a more targeted way to manage their health outside of a clinical setting.
Results from the Phase 3 VISIONARY trial demonstrate the drug's potential, showing that patients achieved a 51% reduction in urine protein levels after nine months of treatment.
Because high protein leakage is a primary indicator of kidney damage, this reduction is a major breakthrough in slowing disease progression. While researchers are still monitoring the long-term impact on dialysis prevention, the safety profile remains manageable, with the most common side effects being minor infections and injection site reactions. This approval signals a new era of personalized care for those living with the high-risk complications of IgAN.
source: U.S. Food and Drug Administration. (2025). FDA Grants Accelerated Approval to Voyxact (sibeprenlimab-szsi) for Primary Immunoglobulin A Nephropathy.
Credit: Hashem Al-Ghaili
